Filing Category: Delisting/Non-Compliance

Analyst Summary

• Tonix Pharmaceuticals regained compliance with NASDAQ Listing Rule 5550(a)(2).
• The Company’s shares had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days.

Potential Implications

Stock Price

• Continued listing on the NASDAQ Capital Market.

Analyst Summary

• Stran & Company, Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement.
• The company had a compliance period until July 28, 2025, to regain compliance.
• On February 20, 2025, Nasdaq notified the company that it regained compliance with the minimum bid price requirement.
• The closing bid price of the company’s common stock has been at $1.00 per share or greater for 11 consecutive business days.

Potential Implications

Stock Price

• Positive impact on stock price due to regained compliance with Nasdaq listing rules.

Analyst Summary

• FutureTech II Acquisition Corp. received a delisting notice from Nasdaq due to non-compliance with IM-5101-2.
• The company failed to complete a business combination within 36 months of its IPO registration statement’s effectiveness.
• Trading of the Company’s securities on Nasdaq will be suspended at the opening of business on February 26, 2025.
• The Company expects its securities will commence trading on the over-the-counter market on or about February 26, 2025.
• The Company intends to make a listing application for the securities of the combined company to be traded on Nasdaq.

Potential Implications

Stock Price

• Delisting from Nasdaq could negatively impact the stock price.
• Transition to the over-the-counter market may affect liquidity and investor confidence.

Analyst Summary

• Lixte Biotechnology Holdings, Inc. received a letter from Nasdaq on August 19, 2024, indicating non-compliance with the minimum stockholders’ equity requirement of $2,500,000.
• The Company submitted a plan to regain compliance, which included raising equity capital.
• Nasdaq granted an extension until February 18, 2025, to regain compliance.
• As of February 18, 2025, the Company had not regained compliance, leading to a Staff determination letter from Nasdaq.
• The Company intends to appeal and request a hearing before a Nasdaq Hearings Panel.
• The hearing request will stay Nasdaq’s delisting of the Company’s common shares and warrants pending the Panel’s decision.
• The Panel has the discretion to grant an additional extension through no later than August 18, 2025.
• During the appeal process, the Company’s common shares and warrants will continue to trade on The Nasdaq Capital Market under the symbols “LIXT” and “LIXTW”, respectively.

Potential Implications

Stock Price

• Continued trading on The Nasdaq Capital Market under the symbols “LIXT” and “LIXTW” during the appeal process.
• Potential delisting from Nasdaq if the Company fails to regain compliance within the permitted time period.

Analyst Summary

• ChargePoint received a notice from the NYSE for non-compliance with Section 802.01C due to low average closing price.
• The company plans to notify the NYSE by March 5, 2025, of its intent to cure the deficiency.
• ChargePoint may consider a reverse stock split to regain compliance, subject to stockholder approval.
• The notice does not immediately delist the company’s stock, and trading will continue on the NYSE during the cure period.

Opportunities and Risks

• Opportunity: Regain compliance with NYSE listing standards through various measures, including a reverse stock split.
• Risk: Failure to regain compliance could lead to delisting from the NYSE.
• Risk: Stockholder approval is needed for a reverse stock split, which may not be guaranteed.

Potential Implications

Stock Price

• Potential for stock price increase if the company successfully regains compliance with NYSE listing standards.
• Potential for stock price decrease if the company fails to regain compliance and is delisted.

Analyst Summary

• iCoreConnect, Inc. received a deficiency letter from Nasdaq on August 20, 2024, for not complying with the minimum $2,500,000 stockholders’ equity requirement.
• As of February 17, 2025, the Company was still not in compliance with the Equity Rule.
• On February 18, 2025, Nasdaq notified the Company that trading of its common stock will be suspended on February 27, 2025, and a Form 25-NSE will be filed to remove the Company’s securities from listing and registration.
• The Company plans to submit a hearing request to Nasdaq’s Hearings Panel to stay the suspension.

Potential Implications

Stock Price

• Potential negative impact on stock price due to possible delisting from Nasdaq.
• Uncertainty regarding the outcome of the hearing request may cause stock price volatility.

Analyst Summary

• Yoshiharu Global Co. received a delisting notification from Nasdaq due to non-compliance with Listing Rule 5550(b)(1).
• The company’s securities will be suspended on February 27, 2025.
• The company intends to request a hearing to appeal the delisting determination.

Potential Implications

Stock Price

• The delisting notification could negatively impact the company’s stock price.
• The outcome of the hearing with Nasdaq will likely influence the stock price.

Analyst Summary

• Primega Group Holdings Limited received a notification from Nasdaq because its stock price was below $1 for an extended period.
• The company has until September 8, 2025, to regain compliance with Nasdaq’s minimum bid price requirement.
• Primega is evaluating options to regain compliance, including a potential reverse stock split.
• There is no guarantee that the company will be able to regain compliance with Nasdaq’s listing requirements.

Potential Implications

Stock Price

• The notification of non-compliance could negatively impact the company’s stock price in the short term.
• The potential for a reverse stock split could also affect the stock price.